STUDY QUESTION: Are four urinary hCG/menotropin (hMG) and one recombinant preparation characterized by different molecular features and do they mediate specific intracellular signaling and steroidogenesis?
Introduction
hCG is a heterodimeric glycoprotein hormone, supporting pregnancy in primates. hCG is crucial to rescue the corpus luteum from atresia and to maintain progesterone production, thereby ensuring embryo implantation and development (Pierce and Parsons, 1981; Cole, 2012a) . The quaternary structure of hCG is enriched by carbohydrate residues covalently bound to the peptidic chains. They consist of four N-and four Olinked oligosaccharides. Sialic acid content is crucial for receptor binding, hCG biological activity and clearance from maternal circulation (de Medeiros and Norman, 2009) . hCG exerts its biological functions by binding to the lutropin/choriogonadotropin receptor (LHCGR). LHCGR is a G protein-coupled receptor (GPCR) belonging to the rhodopsin/β2-adrenergic receptor subfamily and its activation triggers both G protein-and β-arrestin-mediated pathways (Legardinier et al., 2005; Casarini et al., 2012; Heitzler et al., 2012; Ayoub et al., 2015 Ayoub et al., , 2016 , resulting in downstream steroidogenesis, proliferative, and anti-and proapoptotic signals. β-arrestin 2 is involved in desensitization/internalization events and in downstream ERK1/2 signaling pathways activation (Shenoy and Lefkowitz, 2011; Reiter et al., 2012; Thomsen et al., 2016) . At least four hCG isoforms are detectable in serum and urine samples, differing in oligosaccharides moieties, half-life and biological activity (Kardana et al., 1991; Butler et al., 2001; Cole, 2012b) . Moreover, a hyperglycosylated hCG variant may be secreted by invasive cytotrophoblast cells during the first trimester of pregnancy (Takamatsu et al., 1999) , whose mechanism of action is still under discussion (Berndt et al., 2013; Koistinen et al., 2015) .
Gonadotropins are largely used for ovarian stimulation in assisted reproduction. In particular, hCG may be used to support FSH-induced multifollicular growth and oocyte trigger, in several clinical protocols (Casarini et al., 2016a) . Human menopausal gonadotropin (hMG) was the first preparation used in clinical practice and has been available since the 1950s (Loraine and Brown, 1955) . It was originally purified from pooled urine of post-menopausal female donors and contains both FSH and LH molecules. Other urinary gonadotropins have been developed in the last two decades, providing highly-purified hCG preparations suitable for ARTs. Recombinant gonadotropins, obtained from transfected Chinese hamster ovary (CHO) cell lines, are also used (Siebold, 1996) . Importantly, all these preparations differ in composition, source and purification methods, suggesting that gonadotropin-specific effects may occur (Casarini et al., 2016a) .
The high degree of purification of gonadotropins was demonstrated by previous studies comparing recombinant vs urinary gonadotropins, which revealed no variability in ART performances between these preparations (Youssef et al., 2016) . Moreover, high batch-to-batch consistency may be assumed for both recombinant and urinary preparations, as suggested by biochemical analyses and evaluations of clinical outcomes (Gervais et al., 2003; Hugues and Durnerin, 2005; Wolfenson et al., 2005) . These reports demonstrated the suitability of gonadotropin preparations for ART, although an in-depth molecular characterization and an analysis of their action in vitro has never been published.
Aim of the study
In this study, five urinary and recombinant hCG/hMG preparations were analyzed for biochemical composition and presence of glycosylation isoforms. cAMP production, β-arrestin 2 recruitment and progesterone synthesis were also investigated, in both HEK293 cells transiently expressing LHCGR and human primary granulosa cells naturally expressing LHCGR.
Materials and Methods

Gonadotropin commercial preparations
Four different hCG and one hMG preparations were analyzed: Pregnyl ® 5000 IU (Organon International, Oss, Holland) 
Cell culture and transfection
Both primary cells and transiently transfected cell lines were used. Human primary granulosa lutein cells (hGLC) were isolated from ovarian follicles of women undergoing oocyte retrieval for ART. Patients had to match the following criteria: absence of endocrine abnormalities and viral/bacterial infections, age between 25 and 45 years. Cells were recovered using a 50% Percoll density gradient (GE Healthcare, Little Chalfont, UK), following a validated protocol (Casarini et al., 2012 (Casarini et al., , 2014 (Casarini et al., , 2016b . hGLC from three to four patients were pooled and cultured 5-6 days before experiments to recover LHCGR expression (Nordhoff et al., 2011) . Cells were cultured at 37°C and 5% CO 2 in McCoy's 5 A medium, supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml Fungizone (all from Sigma-Aldrich). HEK293 cells were grown in complete DMEM medium supplemented with 10% FBS, 4.5 g/l glucose, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 1 mM glutamine (Invitrogen, Carlsbad, CA, USA). Transient transfections were performed in 96-well plate using Metafectene PRO (Biontex Laboratories GmbH, München, Germany), following the manufacturer's instructions. Briefly, 100 ng/well plasmid and 0.5 μl/well of Metafectene PRO were mixed in serum-free medium and incubated 20 min. A 50 μl plasmid-Metafectene PRO mix was added to each wells containing 1 × 10 5 cells, in a total volume of 200 μl/well, and incubated 2 days before stimulation by gonadotropins. All of the preparations were tested together in each experimental replicate to avoid results biased by patient-specific cell response or HEK293 cells transfection.
Ethical approval
Study approval from the local Ethic Committee was obtained (No. 796, 19 June 2014, released by Comitato Etico Provinciale, Reggio Emilia, Italy). Donors were anonymous and signed a written consent.
Immunoassay to quantify hCG content hCG immunoreactivity of commercial preparations was evaluated by immunoenzymatic sandwich assay (#A85264, Access Immunoassay Systems; Beckman Coulter Inc., Brea, CA, USA) calibrated against the hCG standard (Fifth IS; NIBSC 07/364), following the manufacturer's instructions. Briefly, hCG immobilization on paramagnetic particles occurs by binding to a mouse monoclonal anti-hCGβ antibody in complex with a goat anti-mouse IgG. A rabbit anti-hCGβ alkaline phosphatase conjugate is added and reacts with the immobilized hCG, which is retained unlike the unbound materials. Specifically, serial dilutions starting from 5000 mIU/ml of all the samples were loaded within the same assay, following the IU dosage determined by the suppliers (using in vivo bioassays). Light emission occurring upon addition of Lumi-Phos* 530 chemiluminescent substrate (Lumigen Inc., Beckman Coulter Inc.) is measured by a DxI 800 luminometer (Beckman Coulter Inc.) and compared against the multi-point calibration curve of the hCG standard (Fifth IS; NIBSC 07/364) (Vankrieken and De Hertogh, 1995) . The Supplier provided approximate reactivity to the following hCG preparation as follows: intact hCG (WHO 9/688) 109%; free hCGβ (WHO 99/650)~193%; nicked intact hCG (WHO 99/642)~127%; nicked free hCGβ subunit (WHO 99/692)~127%; free α-subunits and β-core fragments, not detectable.
FSH and LH were measured using an ARCHITECT chemiluminescent immunoassay system (Abbot Diagnostics; Abbott Park, Chicago, IL, USA), where the calibrators were standardized against first IS WHO 92/510 and second IS WHO80/522, respectively. FSH and LH measurement relied on mouse monoclonal anti-FSHβ and -LHβ antibodies provided in the assay kits (#7K75 and #2P40, respectively; Abbott Diagnostics).
Sds page, silver staining analysis and Western blotting analysis hCG/hMG preparations were resolved on 12% SDS-PAGE. Briefly, samples were loaded according to gonadotropin quantification obtained by immunoassay (0.05-3.00 μg). Gel electrophoresis was performed under denaturing (by heating)-reducing or non-denaturing-reducing conditions, and silver staining and Western blotting analysis was carried out. Silver staining was performed after acrylamide gel electrophoresis. Gels were fixed 1 h by 50% ethanol buffer, 12% acetic acid, 5 × 10 −4 % formalin (all from Sigma-Aldrich). After three washes by 50% ethanol, gels were incubated for 1 min in 0.01% Na 2 S 2 O 3 , followed by a 20 min wash in deionized H 2 O. Gel staining was performed by 0.2% AgNO 3 buffer for 30 min followed by three washes using deionized H 2 O. Signals were developed by 1 h incubation with 3% Na 2 CO 3 buffer, 0.0005% formalin and 4 × 10 −4 % Na 2 S 2 O 3 buffer. Reactions were stopped by washing gels in 50% methanol, 12% acetic acid buffer (Chevallet et al., 2006) . hCG isoforms, LH and FSH detection was performed by 12% acrylamide SDS page Western blotting. Rabbit anti-human polyclonal antibody against hCGβ was used to recognize both free hCGβ-subunits and dimeric hCGs (#A0231; Dako, Agilent Technologies, Santa Clara, CA, USA), and a rabbit anti-human polyclonal antibody against FSHβ/FSH (SAB1304978; Sigma-Aldrich). Signals were detected by a ECL chemiluminescent compound (GE HealthCare, Little Chalfont, UK), then acquired by an image analysis system (VersaDoc Imaging System, Bio-Rad Laboratories Inc., Hercules, CA, USA).
Capillary isoelectric-focusing immunoassay
Isoelectric point (pI) analysis of hCG and hMG preparations was performed by capillary isoelectric-focusing immunoassay (cIEF) on a NanoPro™ 100 instrument (ProteinSimple, San Jose, CA, USA), according to the manufacturer's instructions. Briefly, 0.04 μg of hCG/hMG preparations were resuspended in Bicine/CHAPS Lysis and Sample Diluent (20 mM Bicine pH 7.6, 0.6% CHAPS) supplemented with DMSO inhibitor (#040-510, ProteinSimple). Diluted samples were mixed with Premix G2 pH 3-10 (#040-968; ProteinSimple), pI standard Ladder 1 (pI's 4.0, 4.9, 6.0, 6.4 and 7.3; #040-644; ProteinSimple), and pI standard 5.5 (#040-028; ProteinSimple). hCG isoforms characterized by different pIs were revealed by rabbit anti-human polyclonal antibody against hCGβ-subunit (#A0231; Dako, Agilent Technologies). Average exposure time during signal detection was 240 s.
Lectin ELISA assay
The technique was adapted for hCG according to a previous study (Legardinier et al., 2005) . A micro-titration plate was coated over-night at 4°C with anti-gonadotropin α subunit monoclonal antibody HT13.3 (Bidart et al., 1988) , which recognizes all human α-subunits and glycoprotein hormones, in 0.1 M sodium carbonate/hydrogen carbonate buffer pH = 9.6. The plates was washed by TBS-T buffer (25 mM Tris, 140 mM NaCl, 3 mM KCl, 0.05%, Tween 20; pH = 7.4) and non-specific sites were saturated by 1 h-treatment at room temperature (RT) using TBS-T containing 2% polyvinylpyrrolidone K30 (Fluka, Sigma-Aldrich). Then 1 ng of each hCG preparation was incubated 2 h in 100 μl/well of this saturation buffer, in duplicate. After washing, biotinylated lectins (Vector laboratories Ltd, AbCys Biologie, Paris, France) were placed in the wells for 2 h at RT. The lectins used were: Sambucus nigra agglutinin (SNA), Maackia amurensis agglutinin (MAA), jacalin, ricin, wheat germ agglutinin (WGA) and succinylated WGA. They were diluted in saturation buffer containing 1 mM CaCl 2 , 1 mM MgCl 2 and 1 mM MnCl 2 . The plate was washed and peroxidase labelled NeutrAvidin TM (Pierce, Interchim, Montluçon, France) was added in each well (100 μl in TBS-T), for 1 h at RT. After addition of TMB ELISA peroxidase substrate standard solution (UP664781; Interchim, Montluçon, France) for 15 min at RT, the reaction was stopped with 50 μl/well 2 N H 2 SO 4 , and absorbance was measured at a 450 nm wave length using a spectrophotometer. Values from blanks were substracted from the samples.
Evaluation of cAMP production and β-arrestin recruitment by BRET BRET methods for evaluation of cAMP and β-arrestin recruitment were previously validated (Ayoub et al., 2015) . Briefly, cAMP production was evaluated in living cells by transiently transfecting HEK293 cells by plasmids carrying the LHCGR gene (provided by Professor Alfredo Ulloa-Aguirre, Universidad Nacional Autónoma de México, Mexico City, Mexico) and the BRET-based cAMP sensor CAMYEL (provided by Dr Lily I. Jiang, University of Texas, Dallas, TX, USA). CAMYEL sensor is composed by an inactive cytosolic mutant form of human Epac-1 fused with Renilla luciferase (Rluc) and the green fluorescent protein (GFP) (Jiang et al., 2007; Ayoub et al., 2015) . Upon stimulation by hormone, cAMP binding to exchange proteins activated by cAMP (Epac) results in conformational rearrangements of Rluc-Epac-GFP sensor, leading to a dose-dependent decrease of BRET signal. To assess β-arrestin 2 recruitment, HEK293 cells were transiently transfected with plasmid carryng C-terminal Rluc-tagged LHCGR gene (provided by Dr Aylin C. Hanyaloglu, Imperial College, London, UK) and N-terminal yPET-tagged β-arrestin 2 (provided by Dr Mark G. Scott, Cochin Institute, Paris, France). Upon hormone stimulation, β-arrestin 2 translocates to LHCGR leading to a BRET signal increase. For both cAMP and β-arrestin 2 assays, HEK293 were incubated for 30 min in a total volume of 40 μl/well PBS and 1 mM Hepes, in the presence or in the absence of increasing hCG/hMG doses (10 -10 1 μg/ml range), in the presence of 500 μM 3-isobutyl-1-methylxanthine (IBMX) (#I5879; Sigma-Aldrich), as a phosphodiesterases inhibitor (Lindsey and Channing, 1978) . Total cAMP production was evaluated by ELISA (Cyclic AMP Direct EIA kit, Arbor Assays ® , Michigan, USA), following supplier's instructions, and absorbance values were measured by Victor3 multilabel plate reader (Perkin Elmer Inc., Waltham, MA, USA). Data were entered into a curve fitting software and represented using a log regression analysis, as previously described (Casarini et al., 2016b) .
Evaluation of progesterone synthesis
hGLC were seeded in 24-well plates (5 × 10 4 cells/well) and serumstarved 12 h before treatment. Cells were stimulated for eight or 24 h by increasing doses of hCG/hMG (10 −7 -10 1 μg/ml range). The stimulations were blocked by immediate freezing of the samples, then total progesterone was measured in the supernatants by an immunoassay analyser (ARCHITECT second Generation Progesterone system; Abbot Diagnostics, Chicago, IL, USA).
Statistical analysis
BRET data were represented as 'induced BRET changes' by subtracting the untreated cells 540/480 nm ratio from the values from stimulated cells. Steroid concentrations were represented as ng/ml. All the results were expressed as mean ± SEM and Mann-Whitney's U-test or two-way ANOVA and Bonferroni post-test were performed as appropriate. Values were considered statistically significant for P < 0.05, but lower P values were also indicated. Statistical analysis was performed using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).
Results
Inference of hCG/hMG preparations weight (in grams) from immunoreactivity
The quantification of hCG, in terms of weight units per volume, is crucial to properly compare their molecular diversity and activity in vitro. Indeed, commercial preparations are expressed as IU, as an extrapolation of their biological potency measured in vivo (Bangham and Grab, 1964) . This parameter depends on molecule half-life in vivo, occurring as a result of hCG/hMG molecular heterogeneity and isoforms composition (Furuhashi et al., 1995) . Since these molecular features can not be assumed to be homogeneous among the preparations, a comparison of hCG/hMG activities in vitro between molecules dosed in IU, determined by in-vivo bioassay, is inaccurate. Therefore, the weight of each preparation should be determined by re-calibration against a hCG dosed in weight units (e.g. rhCG Ovitrelle ® 250 μg), which was used as a standard to infer the weight (g) from immunoreactivity (IU). For this purpose, a specific method for hCG quantification was used. Firstly, immunoreactivities of hCG/hMG preparations were determined within the same immunoassay, using a monoclonal antibody against the hCGβ subunit. mIU/ml dosage was extrapolated by data interpolation against the multi-point calibration curve of the hCG standard (Fifth IS; NIBSC 07/364), as expected by the assay and described in the 'Materials and Methods' section. Since the weight of rhCG Ovitrelle ® in micrograms is provided by the supplier, this preparation was used to recalibrate the others, assuming the same immunoreactivity of all the preparations. Specifically, we found that 9544.0 ± 103.3 mIU/ml of rhCG Ovitrelle ® , in terms of 'hCG standard Fifth IS; NIBSC 07/364', corresponds to 384.6 ± 4.2 μg/ml (Table I) . Therefore, rhCG Ovitrelle ® was used to calculate the proportion 1 mIU~0.04 μg, which served to calibrate the weight of the other preparations.
Western blotting and silver staining analysis
Four different hCG and one hMG commercial preparations, quantified by immunoreactivity (Table I) , were loaded onto 12% SDS-PAGE under both denaturing (by heating)-reducing and non-denaturingreducing conditions. hCGβ-related molecules and whole protein content were detected by Western blotting and silver staining (Fig. 1 Fig. 1 ). Silver staining confirmed the patterns observed under both denaturingreducing and non-denaturing-reducing conditions by Western blotting (Fig. 1C and D) . Menopur ® and Pregnyl ® exhibited a more heterogeneous migration profile, characterized by several protein bands at different molecular weights. Moreover, the presence of FSH in the preparations was evaluated by Western blotting ( Fig. 1E and F) . As expected, the FSH band was detected only in hMG Menopur ® and confirmed by rFSH Gonal-F ® (positive control), as well as by immunoassay (Table II) . Lower intensities of FSH bands were observed under non-denaturing-reducing conditions, compared to denaturing-reducing conditions, likely as an effect of decreased accessibility of epitopes to antibody binding. Moreover, the absence of LH signals detectable by silver staining, under denaturingreducing conditions (Fig. 1C) , matches the result obtained by Western blotting (Fig. 1A) and it may be plausibly attributable to the loss of epitopes by denaturation.
Analysis of isoelectric points
pI was evaluated by cIEF in gonadotropin preparations, revealing specific spectrum of pI values (pI = 4.0-9.0 range) with most of the isoforms falling in the acidic range (pI < 7.0) (Fig. 2) . Raw pI and percentage values of each peak, as a proportion of the whole preparation profile, are presented in Table III . All the preparations resulted in a similar pattern of peaks falling within the acidic pH range, with six peaks representing pI < 5.0. Therefore, the Menopur ® isoelectric pattern is consistent with the presence of hCG in the preparation. Interestingly, Gonasi ® and C0434 displayed further peaks at a higher pH range than other preparations (pI = 6.0-9.0), reasonably corresponding to less glycosylated hCG isoforms. Finally, the heterogeneity of peak widths among the preparations revealed that gonadotropin isoforms are quantitatively, differently represented.
Reactivity of gonadotropin preparations to lectin binding
The carbohydrate structure of hCG/hMG preparations was investigated by lectin assay, using a panel of six molecules featured by specific affinity to different glycans (Table IV) . Lectin binding to gonadotropin carbohydrate side chains was evaluated by ELISA. We also tested natural pituitary human LH and FSH as these two gonadotropins are present in Menopur ® and recognized by the coated human anti-α subunit antibody HT13.3. Each preparation displayed different affinity to lectins, revealing distinct glycosylation profiles and binding patterns (Fig. 3) . All tested hCGs reacted with MAA, specific for Neu5Acα2-3Gal glycan structure (Wang and Cummings, 1988) . Interestingly, in our experimental conditions, only Menopur ® reacted with SNA, which is specific for Neu5Acα2-6Gal (Shibuya et al., 1987) . This can be attributed to the presence of human FSH and LH which interact with SNA ( Supplementary Fig. 2 ). Jacalin reacted with all hCG preparations, demonstrating the presence of O-glycan chains (Roque-Barreira and Campos-Neto, 1985; Kabir, 1998; Tachibana et al., 2006; Bai et al., 2015) . Supplementary Fig. 2 ). WGA reacted with all five preparations tested, revealing lower signal intensity in Menopur ® vs C0434 and Ovitrelle ® (two-way ANOVA and Bonferroni post-test; P < 0.05; n = 7). Binding capability dramatically decreased using the WGA succinylated analog, suggesting the presence of sialic acid (Bhavanandan and Katlic, 1979; Monsigny et al., 1979 Monsigny et al., , 1980 . Ricin binding was observed in all the preparations, especially in Menopur ® ,
where the signal achieved higher levels than in Pregnyl ® and C0434
(two-way ANOVA and Bonferroni post-test; P < 0.05; n = 7), indicating the presence of non-sialylated terminal Galβ1-4GlcNAc structures on glycan chains (Green et al., 1987) . The garaph in Fig. 3 is alternatively displayed according to the lectins ( Supplementary Fig. 3 ).
Analysis of cAMP production
Preparation-specific intracellular cAMP production was assessed in living HEK293 cells transiently co-expressing with LHCGR and the BRET-based cAMP sensor by 30-min dose-response experiments (Fig. 4) . Gonasi ® , Menopur ® and C0434 treatment resulted in significantly higher half-maximal effective concentrations (EC 50 ) compared to rhCG Ovitrelle ® (Mann-Whitney's U-test; P < 0.05; n = 4).
Moreover, only C0434 exhibited lower efficacy than Menopur ® (Mann-Whitney's U-test; P < 0.05; n = 4), measured as maximal levels (E max ) of 'induced BRET changes'. Control experiments evaluating FSH activity of Menopur ® demonstrated that this preparation induces cAMP synthesis in FSHR-transfected HEK293 cells, as compared to Gonal-F ® ( Supplementary Fig. 4 ). Ovitrelle ® served as a negative control and failed to induce cAMP production in this setting. Total cAMP was also measured in hGLC, naturally expressing LHCGR (and FSHR). Dose-response experiments were performed and cAMP production was evaluated by ELISA after 3 h of treatment (Fig. 4B) β-arrestin 2 tagged to a variant of the yellow fluorescent protein (β-arrestin 2-yPET). Cells were treated by increasing doses of hCG/hMG preparations and β-arrestin 2 recruitment was evaluated by BRET after 30-min treatment (Fig. 5) . Gonasi ® and C0434 treatment resulted in less potent β-arrestin 2 recruitment compared to Ovitrelle ® , as reflected by higher EC 50 values demonstrated (Mann-Whitney's Utest; P < 0.05; n = 4). The partial agonism of C0434 in recruiting β-arrestin 2 was observed as it led to a significantly lower E max than Ovitrelle ® (Mann-Whitney's U-test; P < 0.05; n = 4 
Evaluation of progesterone production
In hGLC, progesterone synthesis is a cAMP-dependent, physiological event mediated by gonadotropins. Progesterone production was evaluated in 8-h and 24 h-stimulated cells by the drugs, and the steroid was measured using immunoassay (Fig. 6) . Reflecting cAMP production, hCG/hMG preparations differently triggered the early (8-h) progesterone accumulation (Fig. 6A) , revealing different steroidogenic potential retained by the preparations. However, after 24 h of continuous stimulation by gonadotropins, progesterone production achieved a plateau, as previously observed (Nordhoff et al., 2011; Casarini et al., 2014 Casarini et al., , 2016b . Indeed, no significant differences in the 24-h progesterone production were observed among the preparations, demonstrated by the dose-response curves and, accordingly, by similar EC 50 and E max values (Mann-Whitney's U-test; P ≥ 0.05; n = 3).
Discussion
In this study, we compared the biochemical compositions and in-vitro activities of four hCG and one hMG preparations. Except for C0434, which was developed for research use only, these hormones are used together with FSH in ART to promote folliculogenesis and trigger ovulation (Casarini et al., 2016a) . For this purpose, several hCG preparations are commercially available, differing in source and purification procedures, resulting in multiple isoform combinations. While Ovitrelle ® is a human recombinant preparation obtained from transfected CHO cells, Gonasi ® and Pregnyl ® are products purified from urine of pregnant women. C0434 is a hCG developed for research, instead of clinical purpose, and purified from pregnancy urine as well.
As claimed by the Supplier in the drug's leaflet, Menopur ® is a purified mixture of human menopausal gonadotropins, therefore containing pituitary hCG, differently from the other preparations which feature hCG of trophoblast origin. This is in contrast with a previous report assuming that 'relatively high amount of hCG can only be explained by assuming the addition of HCG from external sources' in Menopur ® (van de Weijer et al., 2003) , while another study suggested that hCG from pregnant women is added only when it is necessary to achieve the 1:1 FSH to LH activity ratio (Di Stefano et al., 2016 (Storring et al., 1981 (Storring et al., , 1982 , where steroid-dependent endpoints are evaluated (e.g. organ weight) and a different gonadotropin-specific signaling due to rodent receptors may occur (Riccetti et al., 2017a) . Therefore, to analyze and compare their induced-signaling in vitro, we first determined the hCG molar quantities of each preparation by immunoassay against a standard and assuming similar immunoreactivity of different isoproteins (Berger and Lapthorn, 2016) . This approach revealed wide heterogeneity in hCG quantification among the preparations. In particular, FSH and LH immunoreactivity demonstrated in Menopur ® (van de Weijer et al., 2003) supports that these gonadotropins contribute to the drug activity in vivo. In addition, hCGβ subunits were evaluated by Western blotting under both native and denaturing-reducing conditions, revealing specific profiles consisting of a number of hCG bands, ranging between the molecular weights of 20-50 KDa. Under native conditions, a 45 KDa hCG isoform was abundant among all the preparations, as a likely hyperglycosylated heterodimer. The presence of 45 KDa hCG proteins was confirmed by silver staining. Additional bands were also detected in Pregnyl ® and Menopur ® preparations potentially corresponding to distinct isoforms or degradation products. These results support previous studies reporting at least six hCG variants in addition to the 37 KDa 'classical' choriogonadotropin (Kovalevskaya et al., 1999; Butler et al., 2001; Cole, 2012b) . Heterogeneous patterns of pI values were detected by cIEF. Given that sugar structures contribute to increased acidity of hCG, the analysis of isoelectric point suggests the presence of different glycosylation isoforms among drugs. Each hormone exhibited six peaks within the acidic pH range (pI < 5), while the extractive preparations Gonasi ® and C0434 were characterized by additional peaks with more alkaline profiles (pI > 6) reasonably corresponding to poorly glycosylated hCG isoforms. Isoelectric pattern of gonadotropin preparations depends on the purification procedures (Storring et al., 1982) , physiological status of the donor subject Van Damme et al., 1977; Wide, 1985) , as well as generation of degradation artefacts , leading to preparations with multiple hCG variants whose Figure 2 hCG isoforms separation by capillary isoelectric-focusing immunoassay. Isoelectric points (pI) of 0.04 μg hCG/hMG preparations were analyzed revealing different rates of acidic residues. hCG isoforms were detected by rabbit anti-hCGβ polyclonal antibody. Peaks represent increasing acidic hCG isoforms, according to the direction right-to-left on x-axis.
biological activity remains a debated matter (Arey and López, 2011) . In particular, a spectrum of differently glycosylated hCGs were found over the first trimester of pregnancy, when these molecules plausibly mediate trophoblast invasion and cell proliferation (Evans et al., 2015) . Previous studies demonstrated a wide range of hCG isoforms in plasma, urine or in media of cultured cells (Berger et al., 1993; Díaz-Cueto et al., 1994) , when attempting to isolate the molecules corresponding to each peak and to investigate their effects in vitro (Ulloa-Aguirre et al., 1990). Further analysis of hCG drugs by combining massspectrometry, tandem mass tag labeling and a multivariate analysis, revealed different O-and N-linked glycans between urinary and recombinant gonadotropins, moreover, providing a method suitable for glycoprotein characterization (Zhu et al., 2017) . More basic isoforms mediate higher cAMP and/or steroids production increases than more acidic variants, as shown by our finding in hGLC using However, these molecules should be analyzed separately in in-vitro models to fully understand their activity. The glycosylation type was evaluated in gonadotropin preparations by reactivity to six lectins. Human α subunit bears two N-glycan chains while hCGβ has two N-glycan and four O-glycan chains bound to protein backbone (Kobata, 1988) . However, variation in glycan structures exist, depending on the hormone source (Bousfield et al., 2014b) . We show sialylation in α2-3 position on terminal Galactose of the tested hCG extracted from urine. Sialyl α2-6 osberved in Menopur ® may be attributed to FSH present in this preparation. Glycosylation of recombinant gonadotropins depends on the cellular type used to produce them: CHO-K1 cells do not sialylate at position 2-6 of terminal galactose because of a lack of galactoside α-2,6-sialyltransferase (ST6Gal) gene expression (Xu et al., 2011) . Heterogeneity of peaks obtained in IEF might be explained by different sialylation rate of the preparations, which are associated with the presence of desialylated glycan chains. Jacalin is also an useful tool to evaluate O-glycosylation of hCG (Bai et al., 2015) . In our experimental conditions, it detects hCG in Menopur ® while human FSH and LH do not bind jacalin. Indeed, the preparations displayed different pattern of affinity to lectins. ing data have been reported about the role of sugar moieties on receptor binding and hormone activity in vitro (Browne et al., 1990; Bishop et al., 1994; Bousfield et al., 2004; Wehbi et al., 2010) , suggesting that they may impact half-life and immunoreactivity in vivo (Fares, 2006) . Moreover, in Menopur ® , the presence of FSH and LH molecules may result in modulation of hCG-specific cell responses in vitro, as previously suggested (Zhang et al., 2009; Casarini et al., 2016b) . The relevance of gonadotropin glycosylation variants on receptor binding and cell signaling activation in vitro, as well as their physiological role in vivo, is a controversial matter currently debated. Several studies have attempted to characterize the activity of different hCG glycoforms secreted during pregnancy (Guibourdenche et al., 2010; Berndt et al., 2013; Fournier et al., 2015) , as well as that of hypo-and fully glycosylated human FSH, both in vitro and in FSHβ-knock out mice in vivo (Wehbi et al., 2010; Bousfield et al., 2014a; Wang et al., 2016) . We proceeded by analyzing hCG/hMG preparations-induced cell signaling in terms of cAMP production, β-arrestin 2 recruitment and the downstream steroidogenesis in either HEK293 cells transiently expressing LHCGR and hGLC in vitro. All the preparations induced cAMP accumulation and β-arrestin 2 recruitment in the pM and nM range, respectively, confirming the hCG dose shift between the two intracellular endpoints, as previously demonstrated (Ayoub et al., 2015; Riccetti et al., 2017b) . rhCG Ovitrelle ® exhibited higher potency but similar efficacy in inducing cAMP accumulation than some urinary preparations, in both cell models (Figs 4 and 6). Interestingly, gonadotropin-specific cAMP production may be dependent on the source cell, i.e. CHO cells for Ovitrelle ® and trophoblast or pituitary cells for urinary preparations, leading to specific patterns of posttranslational modification of the molecules. Ovitrelle ® and Pregnyl ® were more potent than Gonasi ® and C0434 in triggering β-arrestin 2 recruitment (Fig. 5) . Interestingly, C0434 displayed partial agonism in both cAMP production and β-arrestin 2 recruitment, as shown by its lower E max than that of the other drugs. This matches with the heterogenous signals obtaind by Western blotting, silver staining and cIEF for C0434, suggesting the presence of contaminants and/or partially degraded forms in the preparation. In addition, differences in hCG isoform composition might be responsible of these different pharmacological activities. Previous comparisons between LH and hCG in Figure 3 Comparison of hCG/hMG preparations affinity to lectins.
hCG/hMG lectin binding pattern was evaluated by ELISA. Data are represented as means ± SEM. Differences were considered significant for P < 0.05 (two-way ANOVA and Bonferroni post-tests; n = 7). * = different vs Menopur ® -Jacaline signal (P < 0.001); § = different vs human and goat primary granulosa cells revealed that the two molecules are not equivalent in vitro, resulting in higher hCG-than LHmediated steroidogenic and pro-apoptotic activity, while LH preferentially activates proliferative and anti-apoptotic signals (Casarini et al., 2012 (Casarini et al., , 2016b Gupta et al., 2012) . These data demonstrated that ligand-dependent signaling may be exerted by the same receptor. hCG-specific activity in vitro was amplified in the presence of 10 nM FSH, suggesting FSHR/LHCGR heterodimerization and cross-talk between intracellular signaling pathways (Casarini et al., 2016a) . However, we found that Menopur ® did not result in a more potent or efficient cell signaling activation than the other hCGs. This could potentially reflect balanced FSH and LH co-activity, or sub-optimal FSH dosage for in-vitro evaluations. Interestingly, looking at the hCG-induced progesterone responses after 8 h treatment, the differences measured between the preparations were in line with cAMP production, highlighting the contribution of glycoforms composition in modulating the early steroids production downstream cAMP/PKA pathway activation (Fig. 6A) . This is consistent with previous studies demonstrating matching between intracellular signaling and steroid synthesis in vitro (Casarini et al., 2014 (Casarini et al., , 2016b Ayoub et al., 2016; Riccetti et al., 2017a) . However, hCG/hMG preparations treatment resulted in similar progesterone production after 24 h treatment (Fig. 6B) . As previously observed (Casarini et al., 2016b) , the long-term-cumulative effect on steroidogenesis upon gonadotropins stimulation could mask the differences observed in upstream signaling induced by the hCG/hMG preparations, resulting in a similar steroidogenic potential observed in vitro and in vivo. Indeed, the calibration of commercial gonadotropins relies on their in-vivo activity (Pharmacopea) and can be reached with different mixtures of isoforms presenting heterogeneous half-lives and receptor binding activities. Here, we demonstrate that commercial hCG preparations, while presenting different assortments of isoforms, ultimately exhibit similar steroidogenic activity in vitro, despite triggering different pharmacological activities on upstream signaling events.
Taken together, the converging effects on progesterone synthesis evaluated in vitro demonstrate that methods for therapeutic hCG/ hMG development and purification result in compounds reliably usable for clinical purpose in human. This is confirmed by studies comparing the impact of these preparations on clinical outcomes, such as live birth rate, pregnancy rate or cases of ovarian hypertimulation syndrome, which are not affected by the source of the hCG/hMG preparation used for ART (Youssef et al., 2016) . Interestingly, a specific, gonadotropin-dependent impact on ART outcomes was found by a recent meta-analysis (Santi et al., 2017) . This study evaluating data from a relatively high number of articles (n = 70), demonstrated that the highest oocyte number may be achieved using FSH alone. The addition of hMG should improve the recovery of mature oocytes, embryos and implantation rate, while the addition of LH is linked to a higher pregnancy rate. Therfore, hCG/hMG preparations display different intracellular signaling, however without impacting on ART outcomes, while different gonadotropin molecules may reflect specific clinical actions (Santi et al., 2017) according to in-vitro data (Casarini et al., 2012 (Casarini et al., , 2016b Riccetti et al., 2017a,b) . As a future perspective, results from cell signaling analysis may provide information useful for personalized treatment of patients. It is known that singlenucleotide polymorphisms and mutations falling within the gonadotropin receptor genes may modulate the cell response to the hormones, e.g. cAMP production and ovarian stimulation (Tranchant et al., 2011; Casarini et al., 2014) . Similarly, pathological conditions, such as polycystic ovary syndrome, may benefit from treatment aimed to specific intracellular targets (Rice et al., 2013) , suggesting that gonadotropins mediating specific signal transduction may be suitable for this purpose.
Conclusions
This study demonstrates heterogenous composition of recombinant and urine-derived hCG and hMG preparations, most of which are currently used in ART. The drug mediated different cAMP production and β-arrestin 2 recruitment but did not result in differential progesterone production after 24-h treatment in human primary granulosa cells in vitro. However, differences in activating signal transduction pathways and in progesterone production after 8-h treatment suggest that further investigations focused on the kinetics of steroid synthesis mediated by purified isoforms could clarify the contribution of glycosylation on the action of gonadotropins in vitro.
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